Women's perspectives on impact on the post menopause of use of the 52 mg levonorgestrel intrauterine device during the menopausal transition

Abstract

Objectives

To assess perimenopausal users of 52 mg levonorgestrel intrauterine devices (LNG-IUD) regarding the IUD impact after menopause.

Material and methods

a cross-sectional study with users aged 40 and 49 years old, without cognitive impairment that answered a questionnaire regarding worries and benefits after the menopause due to LNG-IUD use.

Results

Almost half of 221 users (52.9%) have concerns that LNG-IUD use could influence aspects after menopause, 111 (50.3%) that the post-menopause symptoms get worse and 92 (41.6%) that interfere with recognition of menopausal symptoms.

Conclusion

Half of perimenopausal LNG-IUD users expressed concerns about how device use could affect post-menopause symptoms.

SHORT CONDENSATION

The 52 mg hormonal-IUD who were at menopausal transition reported worries that the use of the IUD can affect menopausal symptoms. It is important that health professionals can routinely guide these women.

摘要

目的：评估围绝经期放置52 mg左旋诺孕酮宫内节育器（LNG-IUD）的女性关于LNG-IUD对绝经影响的看法。

材料和方法：一项横断面研究, 年龄在40岁和49岁之间没有认知障碍的女性完成了一份关于应用LNG-IUD对绝经影响的担忧及益处的问卷。

结果：221名应用者中, 近一半(52.9%)的人担心LNG-IUD会影响绝经后的某些方面, 111人(50.3%)担心绝经后症状加重, 92人(41.6%)担心干扰对绝经症状的认识。

结论：一半的围绝经期LNG-IUD应用者表达了节育器影响绝经后症状的担忧。

概括

放置52毫克激素-宫内节育器的绝经过渡期女性报告担心应用宫内节育器会影响更年期症状。卫生专业人员常规指导这些女性十分重要。

Keywords:

• LNG-IUD
• 52 mg levonorgestrel intrauterine device
• menopausal transition

Author contributions

JBEV, LB, CRTJ and AP contributed to the design of the study, JBEV, SM and ML were involved in the data collection, data analysis and/or interpretation. Also all authors contributed to manuscript writing/substantive editing and review and approved the final draft of the manuscript.

Disclosure statement

LB received an honorarium from Bayer Pharma as speaker. The other authors declare no conflict of interest.

Additional information

Funding

This study received partial financial support from the Fundação de Apoio à Pesquisa do Estado de São Paulo (FAPESP) award No. 2015/20504-9 and from the Brazilian National Research Council (CNPq) grant No. 573747/2008-3. The LNG-IUDs used at our clinic have been donated by the International Contraceptive Access Foundation, Turku, Finland, under an unrestricted grant. JV is MSc fellow supported by the SRH, part of the UNDP-UNFPA-UNICEF-WHO-World Bank Special Programme of Research, Development and Research Training in Human Reproduction (HRP), a cosponsored program executed by the World Health Organisation and SM and ML are PhD fellows supported by the Organisation of the American States (OAS). The study funders had no role in the study design, data collection, analysis, interpretation, report writing, or decision to submit the manuscript. This article represents the views of the named authors only and does not represent the views of the mentioned organisations. The funders do not have any participation in the design of the research protocol and the present report.